Treatment with sirolimus is associated with less weight gain after kidney transplantation

Transplantation

Volumn 96, Issue 5, 2013, Pages 480-486

  Diekmann, Fritz ^a   Campistol, Josep M ^a   Rovira, Jordi ^a   Budde, Klemens ^b   Neumayer, Hans Hellmut ^b   Oppenheimer, Federico ^a   Flechner, Stuart M ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Metabolism; mTOR inhibitor; Rapamycin; Sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ARTICLE; BODY MASS; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; VOMITING; WEIGHT GAIN;

ADULT; BLOOD GLUCOSE; CALCINEURIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; TOR SERINE-THREONINE KINASES; WEIGHT GAIN;

EID: 84883559629     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31829a9231     Document Type: Article

References (25)

1. Frei U, Schober-Halstenberg HJ. Nierenersatztherapie in Deutschland. Quasi-Niere Annu Rep 2005/2006
2. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndromeVa new world-wide definition. A consensus statement from the international diabetes federation. Diabetes Med 2006; 23: 469
3. Dobson AJ, Evans A, Ferrario M, et al. Changes in estimated coronary risk in the 1980s: data from 38 populations in the WHO MONICA Project. World Health Organization. Monitoring trends and determinants in cardiovascular diseases. Ann Med 1998; 30: 199
4. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999Y2000. JAMA 2002; 288: 1723
5. Johnson CP, Gallagher-Lepak S, Zhu YR, et al. Factors influencing weight gain after renal transplantation. Transplantation 1993; 56: 822
6. Pischon T, Sharma AM. Obesity as a risk factor in renal transplant patients. Nephrol Dial Transplant 2001; 16: 14
7. Cofa'n F, Vela E, Cléries M. Obesity in renal transplantation: analysis of 2691 patients. Transplant Proc 2005; 37: 3695
8. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547
9. Grundy SM, Hansen B, Smith SC Jr, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related tomanagement. Circulation 2004; 109: 551
10. Liefeldt L, Budde K. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transplant Int 2010; 23: 1191
11. Rovira J, Arellano EM, Burke JT, et al. Effect of mTOR on body weight: from and experimental rat model to human transplant patients. Transplant Int 2008; 21: 992
12. Groth CG, Backman L, Morales JM, et al., for the Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999; 67: 1036
13. Kreis H, Cisterne JM, Land W, et al., for the Sirolimus European Renal Transplant Study Group. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252
14. Kahan BD. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transpl Proc 2003; 35: 37S
15. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633
16. Schena FP, Pascoe MD, Alberu J, et al.; for the Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233
17. Lloberas N, Cruzado JM, Franquesa M, et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17: 1395
18. Herrero-Fresneda I, Torras J, Vidal A, et al. Reduction of postischemic immune inflammatory response: an effective strategy for attenuating chronic allograft nephropathy. Transplantation 2005; 79: 165
19. Tao Y, Kim J, Schrier RW, et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16: 46
20. Um SH, Frigerio F, Watanabe M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431: 200
21. Le Bacquer O, Petroulakis E, Paglialunga S, et al. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 2007; 117: 387
22. Tsukiyama-Kohara K, Poulin F, Kohara M, et al. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat Med 2001; 7: 1128
23. Araki E, Oyadomari S, Mori M. Impact of endoplasmic reticulum stress pathway on pancreatic beta-cells and diabetes mellitus. Exp Biol Med 2003; 228: 1213
24. Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8: 1384
25. Lamming D, Ye Lan, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335: 1638.